Dong-A to receive additional royalty payments over biosimilar drug

Published: 2012-01-18 06:58:00

Updated: 2012-01-18 06:58:00

Dong-A Pharmaceutical Co. is expected to receive additional royalty of its biosimilar drug (Japanese code name: FSK-0808) to treat neutropenia from its partner Gene Techno Science (GTS) in Japan.

GTC’s sublicensees Fuji Pharmaceutical and Mochida Pharmaceutical filed the license application fo...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK